NAMSA, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory, clinical and consulting services, announced that it has been recognized for excellence in clinical research and honored as a 2017 “CRO Leadership Award” winner.
The CRO Leadership Awards are issued by Life Science Leader magazine and are based on data gathered by Industry Standard Research, a full-service biotechnology market research firm. Recipients of this prestigious award are selected based on data-driven feedback from those who have recently utilized clinical services in 27 key CRO performance categories, including Compatibility, Capabilities, Expertise, Quality and Reliability.
“The CROs receiving an award this year are truly at the top of their class, and are deserving of the recognition they receive. Being ranked a top performer demonstrates a level of expertise and commitment to clinical trials and an ability to serve the needs of biopharmaceutical companies and their patients. Medical device sponsors can now make better-informed decisions when selecting a trusted, performance-driven CRO to assist in their clinical trials,” said Ed Miseta, executive editor of Life Science Leader.
“NAMSA is incredibly proud to be recognized by fellow industry executives as a leading CRO. This significant recognition is a direct result of our laser-like focus on accelerating medical device development and commercialization efforts for thousands of clients worldwide,” said John Gorski, NAMSA president & CEO.
For nearly 50 years, NAMSA has focused on helping thousands of global customers succeed by offering the most critical services required to accelerate time-to-market and reduce costs for medical device research. Consistently recognized as a leader in medical device development – with a proven and established track record – NAMSA continuously places a dedicated focus on assisting clients in bringing life-changing therapies to the marketplace in the most efficient manner possible.
“Our experienced teams consistently deliver superior results for clients throughout the full spectrum of product development, including clinical research. By combining the knowledge of our dedicated Associates with our translational research approach, customers not only achieve clinical endpoints more quickly, but are also able to make more effective key commercialization decisions that lead to success,” said Gorski.
NAMSA operates 13 offices throughout North America, Europe, the Middle East and Asia, and employs nearly 1,000 highly-experienced laboratory, clinical and consulting associates.